A plain-language, continually updated guide from Dr. Matt Chalmers’ clinical reference on hormones and peptides.
TB-500 is a synthetic 7-amino-acid fragment (Ac-LKKTETQ) of a much larger, naturally occurring protein called Thymosin Beta-4 — a 43-amino-acid protein your body already makes, involved in how cells move and reorganize during tissue repair.
Here’s the detail almost nobody explains clearly: nearly all of the meaningful clinical research on Thymosin Beta-4 biology was done using the full-length protein — most notably a pharmaceutical formulation called RGN-259, studied in Phase 3 human trials for dry eye disease — not the small fragment that’s actually sold commercially as “TB-500.” That’s an important distinction, because assuming the fragment works the same way the full protein does in the body is an assumption that hasn’t been independently confirmed.
The proposed mechanism for TB-500 centers on the LKKTETQ sequence, the actin-binding region of the parent protein, which is thought to support cell migration by regulating the cell’s internal scaffolding (actin). The strongest human evidence for Thymosin Beta-4 biology comes from a completely different formulation and use case: topical RGN-259 eye drops, studied in Phase 3 trials (ARISE-1 and ARISE-2) for dry eye disease, with mixed results and no full FDA approval as of 2026. Separately, small studies have looked at the full-length protein in cardiac cell therapy and sepsis-related research — again using the full protein, not the injectable fragment.
For the specific use most people search for — musculoskeletal, tendon, and ligament injury recovery — a 2025 orthopedic systematic review confirmed there are no completed Phase 2 or 3 human trials of the fragment for this purpose. This is the single biggest gap between how TB-500 is marketed and what has actually been studied in people. TB-500 also has a long history of veterinary use in horses, but that track record comes from clinical practice patterns, not controlled trials, and several racing jurisdictions have banned it due to its performance-enhancing reputation.
The tissue-remodeling processes studied alongside TB-500 depend on nutrient-driven building blocks elsewhere in the body — vitamin C (a required cofactor for collagen-forming enzymes) and the amino acids proline, glycine, and lysine, which make up collagen’s actual structure.
On April 15, 2026, the FDA removed TB-500 from its 503A Category 2 list (the “significant safety risk” compounding category) — a procedural step, not an approval. TB-500 remains not FDA-approved for any indication and, as of this writing, was not yet authorized for pharmacy compounding. TB-500 is also prohibited at all times under WADA anti-doping rules. The FDA’s Pharmacy Compounding Advisory Committee met July 23–24, 2026 to evaluate whether to add it to the list that would make compounding lawful, and the FDA’s own briefing materials proposed against inclusion, citing gaps in characterization, effectiveness, and safety data. That’s an advisory recommendation, not a final rule. In short: this compound’s legal status remains unresolved, and this page is provided for education only — not an offer to sell or provide TB-500.
There are no completed controlled human trials establishing this for the fragment sold as TB-500. What’s been studied is the full-length parent protein (Thymosin Beta-4) in a different context — eye drops for dry eye disease, and limited cardiac research. For the musculoskeletal recovery use most people are actually curious about, a 2025 systematic review found no completed human trials at all. This is an important gap to understand honestly, not a claim about what TB-500 will do for you.
Both are studied for mechanisms broadly related to tissue-level cellular processes — blood vessel formation for BPC-157, cell migration for TB-500 — which is why they come up together in research and community discussions, even though they act through different pathways.
This page draws on The Pillars Path: A Root-Cause Guide to Hormones, Peptides, and Metabolic Health by Dr. Matt Chalmers — Pillars of Wellness’ clinical reference on hormone and peptide therapy.
